What do systematic reviews say?

Ginkgo biloba vs placebo

• Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 85 participants
  Very low

Ginkgo biloba vs placebo

• Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1154 participants
  Low

Ginkgo biloba vs placebo

• Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Very low

Ginkgo biloba vs placebo

• Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Ginkgo biloba vs placebo

Ginkgo biloba showed no clear difference in other adverse effects (gastrointestinal upset, headache, allergic… compared with placebo (low certainty).

• Ginkgo biloba for tinnitus 2022 · Cochrane Headline outcomes only
  RR 0.91 [0.52, 1.6]
  4 studies · 1175 participants
  Low

Pregabalin 300 mg vs placebo

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 107 participants
  Low

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.85 [0.33, 2.19]
  1 study · 107 participants
  Low

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (vomiting) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.76 [0.35, 1.63]
  1 study · 107 participants
  Low

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (diarrhoea) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.82 [0.38, 1.76]
  1 study · 107 participants
  Low

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in patient satisfaction with analgesia compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.97 [0.42, 2.21]
  1 study · 104 participants
  Low

Pregabalin 300 mg vs placebo

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in patient satisfaction with abortion care overall compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 1.84 [0.8, 4.22]
  1 study · 105 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 1.52 [0.53, 4.37]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg may leads to lower gastrointestinal side effects (vomiting) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.19 [0.04, 0.97]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg showed no clear difference in complete abortion rate compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.69 [0.17, 2.85]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found